Minireviews
Copyright ©The Author(s) 2018.
World J Gastroenterol. Oct 28, 2018; 24(40): 4548-4553
Published online Oct 28, 2018. doi: 10.3748/wjg.v24.i40.4548
Table 1 Regimens for second-line anti-Helicobacter pylori therapy
RegimenDrug
Duration of therapy
PPIBismuthLevoAmoxTetraMetro
Bismuth-containing quadruple therapySD, b.i.d.120 mg, q.i.d.500 mg, q.i.d.500 mg, t.i.d.10-14 d
Levofloxacin-containing triple therapySD, b.i.d.500 mg, q.d.1 g, b.i.d.10-14 d
Levofloxacin-amoxicillin quadruple therapySD, b.i.d.120 mg, q.i.d.500 mg, q.d.1 g, b.i.d.10-14 d
Tetracycline-levofloxacin quadruple therapySD, b.i.d.120 mg, q.i.d.500 mg, q.d.500 mg, q.i.d.10 d
High-dose dual therapySD, q.i.d.750 mg, b.i.d.14 d